Thrombotische Mikroangiopathien

详细信息    查看全文

• 作者：M. Gaggl ; C. Aigner ; G. Sunder-Plassmann…
• 刊名：Medizinische Klinik
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：111
• 期：5
• 页码：434-439
• 全文大小：727 KB
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Internal Medicine
  Medicine/Public Health, general
  
• 出版者：Urban & Vogel
• ISSN：1615-6722
• 卷排序：111

文摘

Thrombotic microangiopathy (TMA) is a clinical syndrome that is characterized by hemolysis, thrombocytopenia, and acute kidney injury, known as atypical hemolytic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), and shigatoxin-associated HUS (STEC-HUS) among others. Several diseases, like malignoma, infections, malignant hypertension, or autoimmune disease can result in secondary TMAs. aHUS is caused by a hyperactivated complement system. Identification of the underlying causes of the TMA is the most important issue and directly associated with treatment success. In case of secondary TMAs, treatment of the actual disease is the most important step, while in case of complement-mediated HUS treatment of choice is plasma exchange or anticomplement agents. For the treatment of TTP, rapid initiation of plasma exchange or plasma infusion is the treatment of choice. Patients with STEC-HUS should solely receive supportive treatment.KeywordsHemolytic–uremic syndrome HemolysisThrombocytopeniaComplement proteinsThrombotic thrombocytopenic purpura